WO1994004139A9 - Treatment of human viral infections - Google Patents
Treatment of human viral infectionsInfo
- Publication number
- WO1994004139A9 WO1994004139A9 PCT/US1993/007879 US9307879W WO9404139A9 WO 1994004139 A9 WO1994004139 A9 WO 1994004139A9 US 9307879 W US9307879 W US 9307879W WO 9404139 A9 WO9404139 A9 WO 9404139A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- group
- unsubstituted
- hydrogen
- hydroxy
- Prior art date
Links
- 206010047461 Viral infection Diseases 0.000 title description 4
- 208000001756 Virus Disease Diseases 0.000 title description 4
- 230000017613 viral reproduction Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 103
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 42
- 239000001257 hydrogen Substances 0.000 claims abstract description 42
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 33
- 241000700605 Viruses Species 0.000 claims abstract description 26
- 125000004404 heteroalkyl group Chemical group 0.000 claims abstract description 26
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 25
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 25
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 22
- 125000005842 heteroatoms Chemical group 0.000 claims abstract description 20
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 16
- 150000002367 halogens Chemical class 0.000 claims abstract description 16
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000126 substance Chemical group 0.000 claims abstract description 11
- 210000004027 cells Anatomy 0.000 claims description 64
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 37
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 32
- ZIUSSTSXXLLKKK-HWUZOJPISA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(\O)=C/C(=O)/C=C/C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-HWUZOJPISA-N 0.000 claims description 28
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 15
- 229960002555 Zidovudine Drugs 0.000 claims description 15
- 229940109262 Curcumin Drugs 0.000 claims description 14
- 235000012754 curcumin Nutrition 0.000 claims description 14
- 239000004148 curcumin Substances 0.000 claims description 14
- 239000000969 carrier Substances 0.000 claims description 13
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- WREGKURFCTUGRC-POYBYMJQSA-N ddC Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 7
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 4
- BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004962 mammalian cells Anatomy 0.000 claims description 2
- 230000000840 anti-viral Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 58
- 239000000203 mixture Substances 0.000 description 27
- 239000003814 drug Substances 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 15
- 229940079593 drugs Drugs 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- PHEDXBVPIONUQT-LQLWEASQSA-N 63597-44-4 Chemical compound C([C@@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-LQLWEASQSA-N 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- -1 e.g. Chemical group 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 208000005721 HIV Infections Diseases 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 201000009910 diseases by infectious agent Diseases 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 102000033180 ERVK-6 Human genes 0.000 description 7
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002609 media Substances 0.000 description 7
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- 230000003612 virological Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 210000000987 Immune System Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000000699 topical Effects 0.000 description 5
- 206010001513 AIDS related complex Diseases 0.000 description 4
- 208000010310 AIDS-Related Complex Diseases 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 239000001963 growth media Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 201000003450 persistent generalized lymphadenopathy Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 101700014779 GLB1 Proteins 0.000 description 3
- 229960002743 Glutamine Drugs 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 125000004001 thioalkyl group Chemical group 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N Foscarnet Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 210000004698 Lymphocytes Anatomy 0.000 description 2
- KUWPCJHYPSUOFW-YBXAARCKSA-N Ortho-Nitrophenyl-β-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 2
- 229920000903 Polyhydroxyalkanoate Polymers 0.000 description 2
- 239000007759 RPMI Media 1640 Substances 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 230000003466 anti-cipated Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920002092 cellular RNA Polymers 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- 102000015609 tat Gene Products Human genes 0.000 description 2
- 108010038756 tat Gene Products Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OJFGQVZAISEIPG-UHFFFAOYSA-N 1,7-bis(3,4-dihydroxyphenyl)hepta-1,6-diene-3,5-dione Chemical compound C1=C(O)C(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=C(O)C(O)=C1 OJFGQVZAISEIPG-UHFFFAOYSA-N 0.000 description 1
- 229940023040 Acyclovir Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- AGPKZVBTJJNPAG-CRCLSJGQSA-N D-allo-isoleucine Chemical compound CC[C@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-CRCLSJGQSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710038044 ERVK-6 Proteins 0.000 description 1
- 101710027967 ERVW-1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001576000 Ero Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710020379 HIV env Proteins 0.000 description 1
- 101710020561 HIV rev Proteins 0.000 description 1
- 102000005319 Human Immunodeficiency Virus tat Gene Products Human genes 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000000801 Human immunodeficiency virus 1 reverse transcriptase Human genes 0.000 description 1
- 108010001522 Human immunodeficiency virus 1 reverse transcriptase Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 101710043203 P23p89 Proteins 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010049025 Persistent generalised lymphadenopathy Diseases 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038997 Retroviral infection Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101710042981 SHMT1 Proteins 0.000 description 1
- 101710023234 Segment 5 Proteins 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000001524 infective Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000000754 repressing Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 125000005156 substituted alkylene group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Definitions
- the human immunodeficiency virus type 1 (HIV-1, also referred to as HTLV-III LAV or HTLV-III/LAV) and, to a lesser extent, human immunodeficiency virus type 2 (HIV-2) is the etiological agent of the acquired immune deficiency syndrome (AIDS) and related disorders.
- AIDS acquired immune deficiency syndrome
- Both HIV-1 and 2 share a similar structural and function genomic organization, having regulatory genes such as tat, rev, nef. in addition to structural genes such as env. gag and pol. hile AIDS, itself, does not necessarily cause death, in many individuals the immune system is so severely depressed that various other diseases (secondary infections or unusual tumors) such as herpes, cytomegalovirus, Kaposi's sarcoma and Epstein-Barr virus related lymphomas among others occur, which ultimately results in death. These secondary infections may be treated using other medications. However, such treatment can be adversely affected by the weakened immune system. Some humans infected with the AIDS virus seem to live many years with little or no symptoms, but appear to have persistent infections.
- PDL persistent generalized lymphadenopathy syndrome
- ARC AIDS related complex
- LTR long terminal repeat
- phorbol 12-myristate-13-acetate (PMA) and Tumor Necrosis Factor- ⁇ (TNF ⁇ ) are believed to be potent activators.
- NF ⁇ is present in markedly enhanced levels in HIV infected individuals, suggesting that the cytokine plays an important role in the pathogenesis of AIDS. Lahdevirta, J., Am. J. Med.. 85:289-291 (1988).
- X is a bond or a hydrogen
- R is selected from the group consisting of hydroxy and substituted alkylene
- Ri through R5 are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstitued alkynyl, a heteroatom such as N, 0, S, and substituted and unsubstituted heteroalkyl.
- the carbon-carbon double bond of a compound of formula I has a trans configuration.
- compounds of the following formula IA are used for purposes of the present invention including for use in treating cells infected by immunodeficiency viruses, preferably human immunodeficiency viruses such as HIV:
- n is an integer from 1 to 20
- X and X' are each independently selected from the group of a bond or a hydrogen
- R-_ through Re are the same as defined above in formula I
- Rg through Ri are each independently selected and defined as said R- ⁇ through Re.
- n is from 1 to 4, and more preferably n is one.
- a specifically preferred compound is curcumin.
- the present invention includes use of compounds of formula IA where one or both of the carbon-carbon double bonds are of a trans configuration as well as where one or both of the carbon-carbon double bonds are of a cis configuration. Compounds of formula IA where both the above depicted double bonds are of a trans configuration are generally more preferred.
- the compounds of the present invention can reduce or inhibit expression of genes operably linked to the LTR of an immunodeficiency virus such as HIV.
- the compounds of the present invention can treat cells infected acutely and chronically by immunodeficiency viruses, for example, HIV, preferably HIV-1, and thus can be used to treat humans infected by HIV.
- immunodeficiency viruses for example, HIV, preferably HIV-1
- These compounds can be used against a different target than the conventional drugs being used to treat humans infected by HIV, e.g., reverse transcriptase inhibitors such as zidovudine (AZT) , 2' ,3' -dideoxyinosine (ddl) and 2' ,3' -dideoxycytidine (ddC) .
- reverse transcriptase inhibitors such as zidovudine (AZT) , 2' ,3' -dideoxyinosine (ddl) and 2' ,3' -dideoxycytidine (ddC) .
- the present compounds should be effective in cells that are resistant to such compounds.
- compounds of the present invention can be used to block HIV-1 LTR directed expression in AZT resistant cell lines.
- the invention also provides pharmaceutical compositions comprising a compound of formula I or IA and a suitable carrier therefor for use in the conditions referred to above.
- Figure 1 shows the inhibitory effects of curcumin (varying concentrations) on TNF ⁇ and PMA induced HIV LTR directed gene expression.
- Figure 2 shows the inhibition of HIV-1 replication by curcumin (varying concentrations) in acutely infected human peripheral blood mononuclear cells.
- R is selected from the group consisting of hydroxy and a substituted alkylene group, e.g., an alkylene group having from 1 to about 15 carbon atoms, more preferably from about 1 to 8 carbon atoms, still more preferable from 1 to about 4 carbon atoms.
- the substituents of said alkylene group suitably may be, for example, halogen such as fluoro, chloro or bromo, alkyl such as alkyl having from 1 to about 12 carbon atoms or from 1 to 6 carbon atoms, alkenyl such as alkenyl having from 2 to 10 carbon atoms or 2 to 6 carbon atoms, alkynyl such as alkynyl having from 2 to about 10 carbon atoms or from 2 to 6 carbon atoms, aryl (including both substituted and unsubstituted aryl) having from 6 to 10 carbon atoms, and N, 0, S, including heteroalkyl, e.g., heteroalkyl having one or more of said he ero atoms and from 1 to 10 carbon atoms or from 1 to 6 carbon atoms.
- halogen such as fluoro, chloro or bromo
- alkyl such as alkyl having from 1 to about 12 carbon atoms or from 1 to 6 carbon atoms
- Ring substituents R-. , R2, 3, 4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom such as N, 0, S, and substituted and unsubstituted heteroalkyl.
- Alkyl ring substituents suitably have from 1 to about 10 carbon atoms, more preferably 1 to 6 carbon atoms.
- Alkenyl and alkynyl phenyl ring substituents suitably have from 2 to about 10 carbon atoms, preferably 2 to 6 carbon atoms.
- Heteroalkyl ring substituents include groups containing one or more hetero atoms linkages and from 1 to about 15 carbon atoms, or from 1 to 8 carbon atoms.
- Preferred heteroalkyl ring substituents are alkoxy, aminoalkyl and thioalkyl groups where the specified heteroatoms is bonded to the aromatic ring and the substituents contain one or more carbon atoms, for example, 1 to about 10 carbon atoms, more preferably from 1 to about 4 carbon atoms.
- Said substituted Ri through Re groups may be substituted at one or more available positions by one or more available groups such as, for example, alkyl groups such as alkyl groups having from 1 to 10 carbon atoms or from 1 to 6 carbon atoms, alkenyl groups such as alkenyl groups having from 2 to 10 carbon atoms or 2 to 6 carbon atoms, substituted and unsubstituted aryl groups having from 6 to 10 carbon atoms, halogen such as fluoro, chloro and bromo, and N, 0 and S, including heteroalkyl, e.g., heteroalkyl having from one or more of N, 0 and/or S linkages (and thus including alkoxy, aminoalkyl and thioalkyl) and from 1 to 10 carbon atoms or from 1 to 6 carbon atoms.
- alkyl groups such as alkyl groups having from 1 to 10 carbon atoms or from 1 to 6 carbon atoms
- alkenyl groups such as alkenyl groups having from 2
- ring is at least mono-substituted, i.e., at least one of Ri through Re is other than hydrogen.
- the phenyl ring suitably may be substituted by more than one group other than hydrogen, for example, di- or tri-substituted by groups other than hydrogen. Hydroxy and lower alkoxy such as methoxy and ethoxy are particularly preferred substituents on the phenyl ring.
- Such a structure may exist, e.g., where the substituent R stabilizes the depicted double bond such as by conjugation and/or intramolecular hydrogen bonding.
- n is an integer suitably from 1 to about 20
- X and X' are each independently selected from the group of a chemical bond (i.e., forms a carbonyl group) and a hydrogen
- R- j _ through R5 are the same as defined above in formula I
- Rg through R ⁇ Q are each independently selected from the group consisting of those groups set forth above to define R-, through Re above, namely, hydrogen, hydroxy, halogen, heteroatom of N, 0, or S, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, and substituted and unsubstituted heteroalkyl.
- n of formula IA is a value of from 1 to 4, and more preferably n is one.
- those compounds of formula IA where one or both of the phenyl rings are at least mono-substituted, i.e. at least one of the substituents - j _ through R- ⁇ Q is other than hydrogen. Further preferred is where both of said depicted rings are at least mono-substituted by a group other than hydrogen.
- One or both of the phenyl rings may be substituted by more than one group other than hydrogen, for example, di- and tri-substituted by groups other than hydrogen. Hydroxy and lower alkoxy such as methoxy and ethoxy are particularly preferred ring substituents.
- each of the above depicted phenyl rings has at least one hydroxy group and at least one alkoxy group such as methoxy or ethoxy.
- Meta and para ring positions are generally preferred positions for substitution of a group other than hydrogen, and more preferred is substitution of a hydroxy group at a para position and an alkoxy group such as methoxy or ethoxy at a meta position.
- the invention includes use of related compounds such as bis(3,4-dihydroxy-cinnamoyl)methane and other diaryl compounds that comprise linkages between the two aryl groups such as alkanoyl, e.g., C ⁇ _**_g-alkanoyl and specifically the group (-CH 2 C(0) (C ⁇ ) ⁇ -) , and alkenoyl, e.g., C- j ⁇ g-alkenoyl and specifically the group (-CH-C-C(O) (CH 2 ) ") .
- the aryl groups of such diaryl compounds are suitably ring substituted with groups such as specified for substituents *- *o ⁇ n reference to formula IA above.
- Curcumin has been used as a food additive for years. Curcumin was isolated in nineteenth century and has been identified as an active component of tumeric, the ground dried thizome of the plant Curcuma Longa Linn. See, Ammon. H.P.T., et al., Pharmacology of Curcuma Longa, Planta Med.. 57. 1-7 (1991). Satoskar, R.R. , International Journal of Clinical Pharmacology. 24, 651-654 (1986); Flynn, D.L. , Prostaglandins Leukotrienes and Medicine. 22:357-360 (1986); Mukhopadhyay, A., et al., Agents and Actions.
- the compounds of the present invention provide effective therapy of chronically infected cells (i.e. cells infected by a virus which is an immunodeficiency virus such as FIV, SIV, HIV, etc.) as evidenced by a reduction in, preferably a complete repression of, e.g. HIV LTR directed gene expression.
- a gene operably linked to the HIV LTR preferably the gene is operably linked to an HIV-1 LTR.
- the term operably linked means that the gene is under the control of the HIV LTR and positioned in a nucleotide sequence to accomplish this.
- the gene is downstream of the LTR, which acts as a promoter.
- the gene corresponds to a viral gene such as the HIV env gene, HIV tat gene, HIV rev gene, etc.
- the present invention can be used in treating those diagnosed as having AIDS as well as those having ARC, PGL and those seropositive but asymptomatic patients.
- a preventative it can also be used prophylactically as a preventative for high risk individuals.
- Compounds of the present invention can be used to treat cells, especially mammalian cells and in particular human cells, infected by an immunodeficiency virus such as HIV infected cells.
- an immunodeficiency virus such as HIV infected cells.
- viral expression is significantly reduced.
- HIV viral expression can be studied by a number of methods such as looking at the expression of a marker gene, e.g. CAT, LacZ, etc., operably linked to the HIV LTR, which acts as the promoter.
- a marker gene e.g. CAT, LacZ, etc.
- Use of the present compounds such as curcumin can significantly reduce expression of such a marker.
- HIV viral expression is turned on and enhanced by HIV LTR stimulators such as tumor necrosis factors- ⁇ (TNF ⁇ ) or phorbol 12-myristate-13-acetate (PMA) .
- TNF ⁇ tumor necrosis factors- ⁇
- PMA phorbol 12-myristate-13-acetate
- One product of this expression, i.e. tat can further augment such viral expression.
- a marker gene such as LacZ operably-linked to the HIV LTR in HIV infected cells
- the addition of an effective amount of compounds of formula I significantly inhibits expression of lacZ gene product, thereby indicating that HIV expression under the control of the HIV LTR such as HIV envelope glycoprotein expression has been inhibited if not completely stopped.
- P 24 a major structural protein (product of gag), has been widely used for monitoring HIV-1 replication in cells and vireamia in individuals.
- the effective amount of a compound of the present invention used to obtain such a result can be at micromolar concentrations. Furthermore, the administration of the compounds of the present invention at effective concentrations, which inhibit HIV expression, has not been found to adversely affect treated cells.
- the compounds of the present invention can be administered to HIV infected individuals or to individuals at high risk for HIV infection. For example, those having sexual relations with an HIV infected partner, intravenous drug users, etc. Because of l ts inhibitory effect, the compounds of the present invention and a pharmaceutical compositions comprising one or more compounds of formula I can be used prophylactically as a method of prevention for such individuals to minimize their risk. One would administer the compound at an effective amount as set forth below by methodology such as described herein.
- compounds of the present invention block activation or suppress activity of HIV-1 LTR and HIV-1 expression in infected cells.
- compounds of the present invention in a dose dependent fashion inhibit HIV LTR directed TNF ⁇ and PMA stimulated gene expression. Moreover, such inhibition is provided with essentially no adverse effects on cell survival or cellular mRNA or total cellular RNA synthesis.
- compounds of the present invention will have utility in inhibiting the progression of an HIV infection and other retroviral infections in cells and in a human, including utility in extending the latency of an HIV infection in humans.
- the absence of cytotoxicity of the compounds of the present invention indicates that these compounds affect positive or negative regulators of LTR such as the HIV LTR, preferably HIV-1 LTR, that are more critical to the retrovirus than the host cell.
- one or more compounds of the invention is administered in an amount sufficient to reduce the amount of protein expressed by the gene by at least about 25 percent relative to an untreated cell, more preferably an amount sufficient to reduce the amount of protein by at least about 50 percent and still more preferably a reduction of the amount of protein expressed by at least about 75 percent relative to an untreated cell.
- a preferred effective dose of one or more compounds of the present invention in particular compounds of formula IA, will be in the range 0.1 mg to 5g per kilogram body weight of recipient per day, more preferably in the range of 0.1 mg to 1,000 mg per kilogram body weight per day, and still more preferably in the range of 1 to 600 mg per kilogram of body weight per day.
- the desired dose is suitably administered once or several more sub-doses administered at appropriate intervals throughout the day, or other appropriate schedule. These sub-doses may be administered as unit dosage forms, for example, containing 100 to 4,000 ⁇ g , preferably 100 to 2,000 ⁇ g.
- a compound of formula I or formula IA is used in accordance with the present invention in an isolated form distinct as it may be naturally found and in a comparatively pure form, e.g., at least 85% by weight pure, more preferably at least 95% pure.
- a comparatively pure form e.g., at least 85% by weight pure, more preferably at least 95% pure.
- administered compound of formula I or IA at least 98% or even greater than 99% pure.
- Such a material would be considered sterile for pharmaceutical purposes.
- Potential contaminants include side products that may result upon synthesis of a compound of the invention or materials that may be otherwise associated with the compound prior to its isolation and purification.
- the present compounds should preferably be sterile and pyrogen free. Purification techniques known in the art may be employed, for example chromatography.
- Administration of the compounds of the invention may be by any suitable route including oral, rectal, nasal, topical (including buccal and sublingual) , vaginal and parenteral (including subcutaneous, intramuscular, intravenous and intradermal) with oral or parenteral being preferred. It will be appreciated that the preferred route may vary with, for example, the condition and age of the recipient.
- the administered ingredients may be used in therapy in conjunction with other medicaments such as reverse transcriptase inhibitors such as dideoxynucleosides, e.g. zidovudine (AZT), 2' ,3'-dideoxyinosine (ddl) and 2' ,3' -dideoxycytidine (ddC) , TAT antagonists such as Ro 3-3335 and Ro 24-7429 protease inhibitors and other agents such as 9-(2-hydroxyethoxymethyl)guanine
- reverse transcriptase inhibitors such as dideoxynucleosides, e.g. zidovudine (AZT), 2' ,3'-dideoxyinosine (ddl) and 2' ,3' -dideoxycytidine (ddC)
- TAT antagonists such as Ro 3-3335 and Ro 24-7429 protease inhibitors and other agents such as 9-(2-hydroxyethoxymethyl)guanine
- interferon e.g., alpha-interferon, interleukin II, and phosphonoformate (Foscarnet) or in conjunction with other immune modulation agents including bone marrow or lymphocyte transplants or other medications such as levamisol or thymosin which would increase lymphocyte numbers and/or function as is appropriate.
- interferon e.g., alpha-interferon, interleukin II, and phosphonoformate (Foscarnet)
- other immune modulation agents including bone marrow or lymphocyte transplants or other medications such as levamisol or thymosin which would increase lymphocyte numbers and/or function as is appropriate.
- the present compounds may be effective when the above-described drugs are not or are no longer effective.
- compounds of the present invention can be used in cells that are resistant to reverse transcriptase inhibitors such as AZT, ddl, and ddC.
- the compounds of formula (I) can be used to block HIV-1 LTR directed LTR expression in such resistant cell lines and for treatment of such resistant strains.
- the present compounds can block HIV-1 LTR directed expression in an AZT resistant strain of HIV-1.
- the present invention can be used therapeutically in an individual as that individual develops resistance to drugs that act on different targets such as AZT, ddl, ddC, R03-3335, etc. It is expected that the present invention can be used for treatment of HIV-1 infected individuals who develop resistance to any drug that targets a different state in the viral life cycle than the present comounds.
- R and R* ⁇ are each independently selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted aryl, and substituted and unsubstituted alkoxy, with particularly preferred compounds of formula II including 3-lapachone (i.e., R and Ri both being hydrogen), and 3-allyl-3-lapachone (i.e., R being allyl and R-, being hydrogen) .
- the alkyl groups preferably have from 1 to about 15 carbon atoms, more preferably from 1 to about 10 carbon atoms, still more preferably from 1 to about 6 carbon atoms.
- alkyl as used in reference to formula II unless otherwise modified refers to both cyclic and noncyclic groups, although of course cyclic groups will comprise at least three carbon ring members.
- Straight or branched chain noncyclic alkyl groups are generally more preferred than cyclic groups.
- Straight chain alkyl groups are generally more preferred than branched.
- the alkenyl groups preferably have from 2 to about 15 carbon atoms, more preferably from 2 to about 10 carbon atoms, still more preferably from 2 to about 6 carbon atoms.
- Especially preferred alkenyl groups have 3 carbon atoms (i.e., 1- ⁇ ropenyl or 2-propenyl) , with the allyl moiety being particularly preferred.
- Phenyl and napthyl are generally preferred aryl groups.
- Alkoxy groups include those alkoxy groups having one or more oxygen linkage and preferably have from 1 to 15 carbon atoms, more preferably from 1 to about 6 carbon atoms.
- Said substituted R and R-i groups may be substituted at one or more available positions by one or more suitable groups such as, for example, alkyl groups such as alkyl groups having from 1 to 10 carbon atoms or from 1 to 6 carbon atoms, alkenyl groups such as alkenyl groups having from 2 to 10 carbon atoms or 2 to 6 carbon atoms, aryl groups having from six to ten carbon atoms, halogen such as fluoro, chloro and bromo, and N, 0 and S, including heteroalkyl, e.g., heteroalkyl having one or more of said hetero atom linkages (and thus including alkoxy, aminolakyl and thioalkyl) and from 1 to 10 carbon atoms or from 1 to
- R, R- ⁇ and R 2 are each independently selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, noncyclic heteroalkyl, and substituted and unsubstituted alkenyl, provided at least two of the substituents of R, R-, and R 2 are other than hydrogen; with particularly preferred compounds of formula III including Topotecan (i.e., the compound of formula III where R is hydrogen, Rl is 9-hydroxyl, and Ro is 10-N-N-diraethyl(methylene)amino (i.e., (CH 3 ) 2 NCH 2 -) , and the compound of formula III where R is ethyl, R-i is hydrogen and R 2 is 9-hydroxyl, wherein said 9- and 10- prefixes refer to positions of ring members as indicated in formula III above.
- Topotecan i.e., the compound of formula III where R is hydrogen, Rl is 9-hydroxyl, and Ro is 10-N-N-diraethyl
- the alkyl groups preferably have from 1 to about 12 carbon atoms, more preferably from about 1 to 6 carbon atoms.
- the term alkyl as used in reference to formula III unless otherwise modified refers to both cyclic and noncyclic groups, although of course cyclic groups will comprise at least three carbon ring members.
- Straight or branched chain noncyclic groups are generally more preferred than cyclic groups.
- Straight chain alkyl groups are generally more preferred than branched.
- the alkenyl substituents preferably have from 2 to about 12 carbon atoms, more preferably from 2 to about 6 carbon atoms.
- Heteroalkyl groups include those noncyclic groups that comprise one or more hetero atoms and each hetero atom has one or more alkyl linkages such as alkyl linkages having from 1 to 8 carbon atoms or 1 to 4 carbon atoms.
- suitable heteroalkyl groups include those where a hetero atom is directly bonded to the general ring system of formula I as well as those groups where a hetero atoms is spaced from the ring system by an alkylene linkage of, e.g., one to four carbon atoms.
- heteroalkyl groups include aminoalkyl groups including primary, secondary and tertiary alkylamines, and especially preferred are N-N-dialkyl(alkylene)amino groups, e.g., groups of the formula (alkyl) 2 N(CH ) n - where n is an integer of 1 to 4.
- N-N-dialkyl(alkylene)amino groups e.g., groups of the formula (alkyl) 2 N(CH ) n - where n is an integer of 1 to 4.
- N-N-dimethylmethyleneamino N-N-dimethylmethyleneamino.
- nonylic heteroalkyl
- Said substituted R, Ri and R 2 groups may be substituted at one or more available position by one or more suitable groups such as, for example, halogen such as fluoro, chloro or bromo, alkyl such as alkyl having from 1 to 12 carbon atoms or from 1 to 6 carbon atoms, alkenyl such as alkenyl having from 2 to 10 carbon atoms or 2 to 6 carbon atoms, aryl having from 6 to 10 carbon atoms, and N, 0, S, including heteroalkyl, e.g., heteroalkyl alkyl having one or more of said hetero atoms and from 1 to 10 carbon atoms or from 1 to 6 carbon atoms.
- suitable groups such as, for example, halogen such as fluoro, chloro or bromo, alkyl such as alkyl having from 1 to 12 carbon atoms or from 1 to 6 carbon atoms, alkenyl such as alkenyl having from 2 to 10 carbon atoms or 2 to 6 carbon atoms, ary
- the present invention includes use of both racemic mixtures and optically active stereoisomers of compounds of formula III.
- optically active compounds where the chiral carbon of the lactone moiety (i.e., the ring carbon of position 4 as depicted in formula III above) is of the (R) configuration according to the Cahn-Ingold-Prelog nomenclature system. See Carey, F.A. , Advanced Organic Chemistry. Part A, p. 65-66 (2d ed., Plenum Press 1984).
- Such compositions of compounds of formula I or IA used in combination with one or more compounds of formula II and/or III may be employed alone or in combination with acceptable carriers such as those described below.
- suitable effective dose of a compound of formula II in such a composition will be in the range of 1 to 5,000 ⁇ g per kilogram body weight of recipient per day, preferably in the range of 10 to 4,000 ⁇ g per kilogram body weight of recipient per day; and a suitable effective dose of a compound of formula III in such a composition will be in the range of 0.4 to 10,000 ⁇ g per kilogram body weight of recipient per day, preferably in the range of 5 to 500 ⁇ g per kilogram body weight of recipient per day.
- the compounds are administered together it is expected one can use the lower portion of these ranges with excellent results.
- One or more compounds of formula I or formula IA may be administered alone, or as part of a pharmaceutical composition, comprising at least one compound of formula I or IA together with one or more acceptable carriers thereof and optionally other therapeutic ingredients, including those therapeutic agents discussed. supra such as one or more compounds of formula II or III.
- the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- compositions include those suitable for oral, rectal, nasal, topical (including buccal and sublingual) , vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.
- the formulations may conveniently be presented in unit dosage form, e.g., tablets and sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the to be administered ingredients with the carrier which constitutes one or more accessory ingredients.
- the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, liposomes or finely divided solid carriers or both, and then if necessary shaping the product.
- compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion, or packed in liposomes and as a bolus, etc.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
- compositions suitable for topical administration include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and outhwashes comprising the ingredient to be administered in a suitable liquid carrier.
- Compositions suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising one or more compounds of the present invention and a pharmaceutically acceptable carrier.
- a suitable topical delivery system is a transdermal patch containing the ingredient to be administered.
- compositions suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- compositions suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size, for example, in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. , by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Suitable formulations wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
- compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.
- HIV-1 was obtained from the culture supernatant of HTLV-III B -producing H9 (H9/HTLV-III B ) cells. During the exponential phase of growth, cell free supernatant was harvested, standardized for reverse transcriptase (RT) activity, and frozen in aliquots at -70°C. Clinical isolates of HIV-1 were prepared from patients testing positive for the human immunodeficiency virus, and standardized for RT activity.
- PNAZ is an expression construct of lacZ gene driven by HIV-1 LTR.
- PBMC peripheral blood mononuclear cells
- FCS Sigma
- penicillin, streptomycin, and L-glutamine in the presence of PHA (3 ⁇ g/ml).
- RPMI 8402 cell line a present from Toshiwo Ando (Aichi Cancer Research Institute, Nagoya, Japan) , is a human T lymphatic cell line. It was grown in RPMI 1640 medium supplemented with 15% FCS and L-glutamine.
- PBMC peripheral blood mononuclear cells
- RTU reverse transcriptase unit
- RNA of HIV-1 reverse transcriptase was assayed with HIV-1 RNA Detection Kit (GeneTrak, Framingham, MA) according to manufacturer's instructions. Briefly, total cellular RNA was prepared, dot blotted onto a nitrocellulose membrane, and hybridized with 32 P labeled probe for RT RNA.
- 293.27.2 cells were plated in 6 well plates at 2 X 10 s cells/well in 2 ml of growth medium (DMEM) .
- TNF ⁇ (40 u/ml) and PMA (2 ng/ml) together with various concentrations of curcumin as indicated in Figure 1 were added to culture media 48 hours after the cells were plated.
- Enzymatic activity is expressed as percentage of maximum expression which is referred to that in drug untreated sample (taken as 100) .
- the cell line OM10.1 contains one copy of HIV-1 per cell integrated into its genome and continually produces a low of HIV-1 proteins. This cell line was kindly supplied by NIH-AIDS Research and Reference Reagent Program.
Abstract
Treatment of cells or humans carrying or infected with a virus capable of causing an immunodeficiency disease with particular compounds including those of formula (IA), wherein the value n is an integer from 1 to 20, X and X' are each independently selected from the group consisting of hydrogen and a chemical bond, and R1 through R10 are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom, and substituted and unsubstituted heteroalkyl.
Description
TREATMENT OF HUMAN VIRAL INFECTIONS
BACKGROUND OF THE INVENTION
The human immunodeficiency virus type 1 (HIV-1, also referred to as HTLV-III LAV or HTLV-III/LAV) and, to a lesser extent, human immunodeficiency virus type 2 (HIV-2) is the etiological agent of the acquired immune deficiency syndrome (AIDS) and related disorders. Barre-Sinoussi, et al., Science. 220:868-871 (1983); Gallo, et al., Science. 224:500-503 (1984); Levy, et al. , Science. 221:840-842 (1984); Popovic, et al. , Science. 224:497-500 (1984); Sarngadharan, et al. , Science. 224:506-508 (1984); Siegal, et al., N. Engl. J. Med.. 305:1439-1444 (1981); Clavel, F. , AIDS. 1:135-140. This disease is characterized by a long asymptomatic period followed by the progressive degeneration of the immune system and the central nervous system. Studies of the virus indicate that replication is highly regulated, and both latent and lytic infection of the CD4 positive helper subset of T-lymphocytes occur in tissue culture. Zagury, et al., Science. 231:850-853 (1986). The expression of the virus in infected patients also appears to be regulated as the titer of infectious virus remains low throughout the course of the disease. Both HIV-1 and 2 share a similar structural and function genomic organization, having regulatory genes such as tat, rev, nef. in addition to structural genes such as env. gag and pol.
hile AIDS, itself, does not necessarily cause death, in many individuals the immune system is so severely depressed that various other diseases (secondary infections or unusual tumors) such as herpes, cytomegalovirus, Kaposi's sarcoma and Epstein-Barr virus related lymphomas among others occur, which ultimately results in death. These secondary infections may be treated using other medications. However, such treatment can be adversely affected by the weakened immune system. Some humans infected with the AIDS virus seem to live many years with little or no symptoms, but appear to have persistent infections.
Another group of humans suffers mild immune system depression with various symptoms such as weight loss, malaise, fever and swollen lymph nodes. These syndromes have been called persistent generalized lymphadenopathy syndrome (PGL) and AIDS related complex (ARC) and may or may not develop into AIDS. In all cases, those infected with the HIV are believed to be persistently infective to others.
The activation of the latent HIV provirus from the asymptomatic period has been reported to be governed by a long terminal repeat (LTR) in the viral DNA. See, e.g. Ranki, A., et al., Lancet ii: 589-593 (1987); Fauci, A.S., et al., Science. 219:617-622 (1988); Zagury, D. , et al. , Science. 231:850-853 (1985); Mosca, J.D., Nature (London), 3_25:67-70 (1987). The activity of HIV-1 is determined by the complex interaction of positive and negative transcriptional regulators that bind to specific sequences within the LTR. Cullen, B.R., et al., Cell. 11:423-426 (1989). Changes in the quantity or quality of these factors may underlie the activation of transcription of HIV-1 and HIV-2 latent provirus by a myriad of stimuli. See, e.g.
Fauci, A.S., Science. 211:617-622 (1988); Griffin, G.E., et al. , Nature (London), 119:70-73 (1989); Nabel, G., et al., Science. 219:1299-1302 (1988). Specifically, phorbol 12-myristate-13-acetate (PMA) and Tumor Necrosis Factor-α (TNFα) are believed to be potent activators. In particular,
NFα is present in markedly enhanced levels in HIV infected individuals, suggesting that the cytokine plays an important role in the pathogenesis of AIDS. Lahdevirta, J., Am. J. Med.. 85:289-291 (1988).
Most known methods for treating individuals infected by HIV have focused on preventing integration of the provirus into the host cell's chromosome. Thus, one area of interest has been drugs that affect reverse transcriptase. Many of the proposed therapeutic methods, however, have not proven clinically effective. Indeed, even treatments that have resulted in clinical utility such as AZT (zidovudine) have not been reported to prevent the breakdown of the immune system in many patients after a number of years of treatment. Few methods have been reported to inhibit both expression of integrated provirus and chronic infection of HIV-1. Reverse transcriptase inhibitors e.g. AZT, ddC, ddl have not been reported to have inhibitory effect on chronic infections. Ro3-3335 was reported to be effective on chronic infection. See Hsu, M-C, Science. 214:1799-1800 (1992).
It thus would be desirable to have a new compound that can treat HIV infected cells. It would be particularly desirable to have a new therapy that can be used to treat cells already infected, by means other than by preventing integration of the virus such as inhibitory expression of provirus, or keeping the provirus dorman within infected cells.
SUMMARY OF THE INVENTION We have now discovered that compounds of the following formula I are useful for treating cells infected by immunodeficiency viruses, preferably human immunodeficiency viruses such as HIV:
wherein X is a bond or a hydrogen, R is selected from the group consisting of hydroxy and substituted alkylene, and Ri through R5 are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstitued alkynyl, a heteroatom such as N, 0, S, and substituted and unsubstituted heteroalkyl. Preferably the carbon-carbon double bond of a compound of formula I has a trans configuration.
In preferred aspects, compounds of the following formula IA are used for purposes of the present invention including for use in treating cells infected by immunodeficiency viruses, preferably human immunodeficiency viruses such as HIV:
wherein the value n is an integer from 1 to 20, X and X' are each independently selected from the group of a bond or a hydrogen, R-_ through Re are the same as defined above in formula I, and Rg through Ri are each independently selected and defined as said R-^ through Re. Preferably the value n is from 1 to 4, and more preferably n is one. A specifically preferred compound is curcumin. The present
invention includes use of compounds of formula IA where one or both of the carbon-carbon double bonds are of a trans configuration as well as where one or both of the carbon-carbon double bonds are of a cis configuration. Compounds of formula IA where both the above depicted double bonds are of a trans configuration are generally more preferred.
The compounds of the present invention can reduce or inhibit expression of genes operably linked to the LTR of an immunodeficiency virus such as HIV.
In one embodiment, the compounds of the present invention can treat cells infected acutely and chronically by immunodeficiency viruses, for example, HIV, preferably HIV-1, and thus can be used to treat humans infected by HIV. For example, treatment of those diagnosed as having AIDS as well as those having ARC, PGL and those not yet exhibiting such conditions.
These compounds can be used against a different target than the conventional drugs being used to treat humans infected by HIV, e.g., reverse transcriptase inhibitors such as zidovudine (AZT) , 2' ,3' -dideoxyinosine (ddl) and 2' ,3' -dideoxycytidine (ddC) . Using such drugs in combination with the present compounds is anticipated to result in a, synergistic result.
Similarly, the present compounds should be effective in cells that are resistant to such compounds. For example, compounds of the present invention can be used to block HIV-1 LTR directed expression in AZT resistant cell lines.
The invention also provides pharmaceutical compositions comprising a compound of formula I or IA and a suitable carrier therefor for use in the conditions referred to above.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the inhibitory effects of curcumin (varying concentrations) on TNFα and PMA induced HIV LTR directed gene expression.
Figure 2 shows the inhibition of HIV-1 replication by curcumin (varying concentrations) in acutely infected human peripheral blood mononuclear cells.
DETAILED DESCRIPTION OF THE INVENTION
We have discovered that compounds of the following formula I can be used to treat cells infected by an immunodeficiency virus, preferably human cells infected with HIV and thus can be used for treatment in HIV infected individuals:
wherein X is a chemical bond (i.e., forms a carbonyl group) or hydrogen, R is selected from the group consisting of hydroxy and a substituted alkylene group, e.g., an alkylene group having from 1 to about 15 carbon atoms, more preferably from about 1 to 8 carbon atoms, still more preferable from 1 to about 4 carbon atoms. The substituents of said alkylene group suitably may be, for example, halogen such as fluoro, chloro or bromo, alkyl such as alkyl having from 1 to about 12 carbon atoms or from 1 to 6 carbon atoms, alkenyl such as alkenyl having from 2 to 10 carbon atoms or 2 to 6 carbon atoms, alkynyl such as alkynyl having from 2 to about 10 carbon atoms or from 2 to 6 carbon atoms, aryl (including both substituted and unsubstituted aryl) having from 6 to 10 carbon atoms, and N, 0, S, including heteroalkyl, e.g., heteroalkyl having one or more of said he ero atoms and
from 1 to 10 carbon atoms or from 1 to 6 carbon atoms. Ring substituents R-. , R2, 3, 4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom such as N, 0, S, and substituted and unsubstituted heteroalkyl. Alkyl ring substituents suitably have from 1 to about 10 carbon atoms, more preferably 1 to 6 carbon atoms. Alkenyl and alkynyl phenyl ring substituents suitably have from 2 to about 10 carbon atoms, preferably 2 to 6 carbon atoms. Heteroalkyl ring substituents include groups containing one or more hetero atoms linkages and from 1 to about 15 carbon atoms, or from 1 to 8 carbon atoms. Preferred heteroalkyl ring substituents are alkoxy, aminoalkyl and thioalkyl groups where the specified heteroatoms is bonded to the aromatic ring and the substituents contain one or more carbon atoms, for example, 1 to about 10 carbon atoms, more preferably from 1 to about 4 carbon atoms. Said substituted Ri through Re groups may be substituted at one or more available positions by one or more available groups such as, for example, alkyl groups such as alkyl groups having from 1 to 10 carbon atoms or from 1 to 6 carbon atoms, alkenyl groups such as alkenyl groups having from 2 to 10 carbon atoms or 2 to 6 carbon atoms, substituted and unsubstituted aryl groups having from 6 to 10 carbon atoms, halogen such as fluoro, chloro and bromo, and N, 0 and S, including heteroalkyl, e.g., heteroalkyl having from one or more of N, 0 and/or S linkages (and thus including alkoxy, aminoalkyl and thioalkyl) and from 1 to 10 carbon atoms or from 1 to 6 carbon atoms.
Generally preferred are those compounds of formula I where the ring is at least mono-substituted, i.e., at least one of Ri through Re is other than hydrogen. The phenyl ring suitably may be substituted by more than one group other than hydrogen, for example, di- or tri-substituted by groups other
than hydrogen. Hydroxy and lower alkoxy such as methoxy and ethoxy are particularly preferred substituents on the phenyl ring.
While compounds having the precise structure of formula I where the double bond is conjugated with the phenyl ring are preferred, as the terms are defined herein compounds coming within formula I include structurally related compounds, including those compounds where the depicted carbon-carbon double bond is migrated to an adjacent carbon, e.g., the compounds of the below structure where the group R and the ring substituents R-^ through R5 are the same as defined above for formula I:
Such a structure may exist, e.g., where the substituent R stabilizes the depicted double bond such as by conjugation and/or intramolecular hydrogen bonding.
Generally more preferred for purposes of the present invention are compounds of the following formula IA:
wherein the value n is an integer suitably from 1 to about 20, X and X' are each independently selected from the group of a
chemical bond (i.e., forms a carbonyl group) and a hydrogen, R-j_ through R5 are the same as defined above in formula I, Rg through RΠQ are each independently selected from the group consisting of those groups set forth above to define R-, through Re above, namely, hydrogen, hydroxy, halogen, heteroatom of N, 0, or S, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, and substituted and unsubstituted heteroalkyl.
Preferably the value n of formula IA is a value of from 1 to 4, and more preferably n is one.
Generally preferred are those compounds of formula IA where one or both of the phenyl rings are at least mono-substituted, i.e. at least one of the substituents -j_ through R-^Q is other than hydrogen. Further preferred is where both of said depicted rings are at least mono-substituted by a group other than hydrogen. One or both of the phenyl rings may be substituted by more than one group other than hydrogen, for example, di- and tri-substituted by groups other than hydrogen. Hydroxy and lower alkoxy such as methoxy and ethoxy are particularly preferred ring substituents. More preferred is where each of the above depicted phenyl rings has at least one hydroxy group and at least one alkoxy group such as methoxy or ethoxy. Meta and para ring positions are generally preferred positions for substitution of a group other than hydrogen, and more preferred is substitution of a hydroxy group at a para position and an alkoxy group such as methoxy or ethoxy at a meta position.
While compounds having the precise structure of formula IA where the depicted carbon-carbon double bonds are conjugated with the phenyl rings are preferred, as used herein, compounds coming within formula IA include structurally related compounds,
JO-
including those compounds where one or more of the depicted carbon-carbon double bonds or carbonyl groups is migrated to an adjacent carbon, e.g., compounds of the following formula IB where the ring substituents Ri through RIQ are the same as described above for formula IA and n is an integer of a value of zero or greater:
Such a structure will be more typical where stabilizing factors exist. For example, where the value n is zero, intramolecular hydrogen bonding and conjugation will stabilize the following compound where the ring substituents are as defined above:
In another embodiment, the invention includes use of related compounds such as bis(3,4-dihydroxy-cinnamoyl)methane and other diaryl compounds that comprise linkages between the two aryl groups such as alkanoyl, e.g., C^_**_g-alkanoyl and specifically the group (-CH2C(0) (C^)^-) , and alkenoyl, e.g., C-j^g-alkenoyl and specifically the group (-CH-C-C(O) (CH2) ") . The aryl groups of such diaryl compounds are suitably ring substituted with groups such as specified for substituents *- *o ^n reference to formula IA above.
Compounds of the present invention can readily be made. See, Merck Index. 417 (11th ed. , 1989); T. Rao et al. , Indian J. Med. Res.. 7_5:574-578 (1982). Other compounds of formula I can be prepared by procedures well known to those skilled in the synthesis art.
One preferred compound, curcumin, has been used as a food additive for years. Curcumin was isolated in nineteenth century and has been identified as an active component of tumeric, the ground dried thizome of the plant Curcuma Longa Linn. See, Ammon. H.P.T., et al., Pharmacology of Curcuma Longa, Planta Med.. 57. 1-7 (1991). Satoskar, R.R. , International Journal of Clinical Pharmacology. 24, 651-654 (1986); Flynn, D.L. , Prostaglandins Leukotrienes and Medicine. 22:357-360 (1986); Mukhopadhyay, A., et al., Agents and Actions. 12 (4):508-515 (1982); Rao, T.S., et al. , Indian J. Med. Res.. 75:574-578 (1982); Sharma, O.P. , Biochemical Pharmacology. 21:1811-1812 (1976); Koch, R.T., Eine Droge Zyr Gebrauch gegen Erkankungen der Gallenwege und der leber, Munch Med. Wschr.. 972 (1927). Curcumin and certain related compounds have been reported to exhibit antiinflammatory activity. Thus, its use, and the use of related compounds is expected to pose little, if any, health risks and have at most extremely minor side effects.
It is believed that the compounds of the present invention provide effective therapy of chronically infected cells (i.e. cells infected by a virus which is an immunodeficiency virus such as FIV, SIV, HIV, etc.) as evidenced by a reduction in, preferably a complete repression of, e.g. HIV LTR directed gene expression. Thus, in an HIV infected cell addition of an effective amount of a compound of the present invention will reduce the expression of a gene operably linked to the HIV LTR. Preferably the gene is operably linked to an HIV-1 LTR. As used herein, the term operably linked means that the gene is under the control of the HIV LTR and positioned in a nucleotide
sequence to accomplish this. Typically, the gene is downstream of the LTR, which acts as a promoter. Preferably, the gene corresponds to a viral gene such as the HIV env gene, HIV tat gene, HIV rev gene, etc.
Hence, in one preferred embodiment the present invention can be used in treating those diagnosed as having AIDS as well as those having ARC, PGL and those seropositive but asymptomatic patients. For example, as a preventative, it can also be used prophylactically as a preventative for high risk individuals.
Compounds of the present invention can be used to treat cells, especially mammalian cells and in particular human cells, infected by an immunodeficiency virus such as HIV infected cells. As a result of treatment with compounds of the present invention viral expression is significantly reduced.
For example, HIV viral expression can be studied by a number of methods such as looking at the expression of a marker gene, e.g. CAT, LacZ, etc., operably linked to the HIV LTR, which acts as the promoter. Use of the present compounds such as curcumin can significantly reduce expression of such a marker. HIV viral expression is turned on and enhanced by HIV LTR stimulators such as tumor necrosis factors-α (TNFα) or phorbol 12-myristate-13-acetate (PMA) . One product of this expression, i.e. tat can further augment such viral expression. Using a marker gene such as LacZ operably-linked to the HIV LTR in HIV infected cells, the addition of an effective amount of compounds of formula I significantly inhibits expression of lacZ gene product, thereby indicating that HIV expression under the control of the HIV LTR such as HIV envelope glycoprotein expression has been inhibited if not completely stopped.
P24, a major structural protein (product of gag), has been widely used for monitoring HIV-1 replication in cells and
vireamia in individuals. Use of present compounds such as curcumin, at concentrations that do not adversely affect cells, can dramatically reduce HIV-1 replication, e.g. preferably a reduction of HIV-1 replication of more than 25% as determined by P24 levels, more preferably a reduction of more than 50%, and still more preferably a reduction of HIV-1 replication of more than 80% as determined by P24 levels.
The effective amount of a compound of the present invention used to obtain such a result can be at micromolar concentrations. Furthermore, the administration of the compounds of the present invention at effective concentrations, which inhibit HIV expression, has not been found to adversely affect treated cells.
The compounds of the present invention can be administered to HIV infected individuals or to individuals at high risk for HIV infection. For example, those having sexual relations with an HIV infected partner, intravenous drug users, etc. Because of lts inhibitory effect, the compounds of the present invention and a pharmaceutical compositions comprising one or more compounds of formula I can be used prophylactically as a method of prevention for such individuals to minimize their risk. One would administer the compound at an effective amount as set forth below by methodology such as described herein.
As demonstrated in the examples which follow, compounds of the present invention block activation or suppress activity of HIV-1 LTR and HIV-1 expression in infected cells. In particular, it has been found that compounds of the present invention in a dose dependent fashion inhibit HIV LTR directed TNFα and PMA stimulated gene expression. Moreover, such inhibition is provided with essentially no adverse effects on cell survival or cellular mRNA or total cellular RNA synthesis. Thus, it is believed compounds of the present invention will
have utility in inhibiting the progression of an HIV infection and other retroviral infections in cells and in a human, including utility in extending the latency of an HIV infection in humans.
While not wishing to be bound by theory, the absence of cytotoxicity of the compounds of the present invention indicates that these compounds affect positive or negative regulators of LTR such as the HIV LTR, preferably HIV-1 LTR, that are more critical to the retrovirus than the host cell.
Preferably, for inhibiting or reducing the expression of genes operably linked to an HIV LTR, one or more compounds of the invention is administered in an amount sufficient to reduce the amount of protein expressed by the gene by at least about 25 percent relative to an untreated cell, more preferably an amount sufficient to reduce the amount of protein by at least about 50 percent and still more preferably a reduction of the amount of protein expressed by at least about 75 percent relative to an untreated cell.
In general for the treatement of immunodeficiency viral infections, for example an HIV infection, a preferred effective dose of one or more compounds of the present invention, in particular compounds of formula IA, will be in the range 0.1 mg to 5g per kilogram body weight of recipient per day, more preferably in the range of 0.1 mg to 1,000 mg per kilogram body weight per day, and still more preferably in the range of 1 to 600 mg per kilogram of body weight per day. The desired dose is suitably administered once or several more sub-doses administered at appropriate intervals throughout the day, or other appropriate schedule. These sub-doses may be administered as unit dosage forms, for example, containing 100 to 4,000 μg , preferably 100 to 2,000 μg.
Preferably a compound of formula I or formula IA is used in accordance with the present invention in an isolated form distinct as it may be naturally found and in a comparatively pure form, e.g., at least 85% by weight pure, more preferably at least 95% pure. For some treatments in accordance with the present invention, it may be desirable that administered compound of formula I or IA at least 98% or even greater than 99% pure. Such a material would be considered sterile for pharmaceutical purposes. Potential contaminants include side products that may result upon synthesis of a compound of the invention or materials that may be otherwise associated with the compound prior to its isolation and purification. The present compounds should preferably be sterile and pyrogen free. Purification techniques known in the art may be employed, for example chromatography.
Administration of the compounds of the invention may be by any suitable route including oral, rectal, nasal, topical (including buccal and sublingual) , vaginal and parenteral (including subcutaneous, intramuscular, intravenous and intradermal) with oral or parenteral being preferred. It will be appreciated that the preferred route may vary with, for example, the condition and age of the recipient.
The administered ingredients may be used in therapy in conjunction with other medicaments such as reverse transcriptase inhibitors such as dideoxynucleosides, e.g. zidovudine (AZT), 2' ,3'-dideoxyinosine (ddl) and 2' ,3' -dideoxycytidine (ddC) , TAT antagonists such as Ro 3-3335 and Ro 24-7429 protease inhibitors and other agents such as 9-(2-hydroxyethoxymethyl)guanine
(acyclovir) , interferon, e.g., alpha-interferon, interleukin II, and phosphonoformate (Foscarnet) or in conjunction with other immune modulation agents including bone marrow or lymphocyte transplants or other medications such as levamisol or thymosin which would increase lymphocyte numbers and/or function as is
appropriate. Because many of these drugs are directed to different targets, e.g., viral integration, it is anticipated that a synergistic result will be obtained by this combination.
Similarly, the present compounds may be effective when the above-described drugs are not or are no longer effective. For example, compounds of the present invention can be used in cells that are resistant to reverse transcriptase inhibitors such as AZT, ddl, and ddC. For instance, the compounds of formula (I), can be used to block HIV-1 LTR directed LTR expression in such resistant cell lines and for treatment of such resistant strains. For example, the present compounds can block HIV-1 LTR directed expression in an AZT resistant strain of HIV-1. Accordingly, the present invention can be used therapeutically in an individual as that individual develops resistance to drugs that act on different targets such as AZT, ddl, ddC, R03-3335, etc. It is expected that the present invention can be used for treatment of HIV-1 infected individuals who develop resistance to any drug that targets a different state in the viral life cycle than the present comounds.
In one preferred embodiment one or more compounds of formulas I or IA are used in conjunction with a compound of the following formula II:
wherein R and R*^ are each independently selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted aryl, and substituted and unsubstituted alkoxy,
with particularly preferred compounds of formula II including 3-lapachone (i.e., R and Ri both being hydrogen), and 3-allyl-3-lapachone (i.e., R being allyl and R-, being hydrogen) . The alkyl groups preferably have from 1 to about 15 carbon atoms, more preferably from 1 to about 10 carbon atoms, still more preferably from 1 to about 6 carbon atoms. The term alkyl as used in reference to formula II unless otherwise modified refers to both cyclic and noncyclic groups, although of course cyclic groups will comprise at least three carbon ring members. Straight or branched chain noncyclic alkyl groups are generally more preferred than cyclic groups. Straight chain alkyl groups are generally more preferred than branched. The alkenyl groups preferably have from 2 to about 15 carbon atoms, more preferably from 2 to about 10 carbon atoms, still more preferably from 2 to about 6 carbon atoms. Especially preferred alkenyl groups have 3 carbon atoms (i.e., 1-ρropenyl or 2-propenyl) , with the allyl moiety being particularly preferred. Phenyl and napthyl are generally preferred aryl groups. Alkoxy groups include those alkoxy groups having one or more oxygen linkage and preferably have from 1 to 15 carbon atoms, more preferably from 1 to about 6 carbon atoms. Said substituted R and R-i groups may be substituted at one or more available positions by one or more suitable groups such as, for example, alkyl groups such as alkyl groups having from 1 to 10 carbon atoms or from 1 to 6 carbon atoms, alkenyl groups such as alkenyl groups having from 2 to 10 carbon atoms or 2 to 6 carbon atoms, aryl groups having from six to ten carbon atoms, halogen such as fluoro, chloro and bromo, and N, 0 and S, including heteroalkyl, e.g., heteroalkyl having one or more of said hetero atom linkages (and thus including alkoxy, aminolakyl and thioalkyl) and from 1 to 10 carbon atoms or from 1 to 6 carbon atoms.
Also preferred is to use one or more compounds of formula I or IA, either alone or in combination with a compound of formula
II such as ^-lapachone, in conjunction with a compound of the following formula III:
wherein R, R-^ and R2 are each independently selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, noncyclic heteroalkyl, and substituted and unsubstituted alkenyl, provided at least two of the substituents of R, R-, and R2 are other than hydrogen; with particularly preferred compounds of formula III including Topotecan (i.e., the compound of formula III where R is hydrogen, Rl is 9-hydroxyl, and Ro is 10-N-N-diraethyl(methylene)amino (i.e., (CH3)2NCH2-) , and the compound of formula III where R is ethyl, R-i is hydrogen and R2 is 9-hydroxyl, wherein said 9- and 10- prefixes refer to positions of ring members as indicated in formula III above.
The alkyl groups preferably have from 1 to about 12 carbon atoms, more preferably from about 1 to 6 carbon atoms. The term alkyl as used in reference to formula III unless otherwise modified refers to both cyclic and noncyclic groups, although of course cyclic groups will comprise at least three carbon ring members. Straight or branched chain noncyclic groups are generally more preferred than cyclic groups. Straight chain alkyl groups are generally more preferred than branched. The alkenyl substituents preferably have from 2 to about 12 carbon atoms, more preferably from 2 to about 6 carbon atoms. Heteroalkyl groups include those noncyclic groups that comprise one or more hetero atoms and each hetero atom has one or more alkyl linkages such as alkyl linkages having from 1 to 8 carbon
atoms or 1 to 4 carbon atoms. Thus suitable heteroalkyl groups include those where a hetero atom is directly bonded to the general ring system of formula I as well as those groups where a hetero atoms is spaced from the ring system by an alkylene linkage of, e.g., one to four carbon atoms. Particularly preferred heteroalkyl groups include aminoalkyl groups including primary, secondary and tertiary alkylamines, and especially preferred are N-N-dialkyl(alkylene)amino groups, e.g., groups of the formula (alkyl)2N(CH )n- where n is an integer of 1 to 4. A particularly perferred gruop is
N-N-dimethylmethyleneamino. The term "noncylic" heteroalkyl, is intended to include straight and branched chain moieties, but not groups that comprise a closed ring structure including those groups that form a ring comprising two or more aromatic carbons at positions 7 to 10 as depicted above in formula III.
Said substituted R, Ri and R2 groups may be substituted at one or more available position by one or more suitable groups such as, for example, halogen such as fluoro, chloro or bromo, alkyl such as alkyl having from 1 to 12 carbon atoms or from 1 to 6 carbon atoms, alkenyl such as alkenyl having from 2 to 10 carbon atoms or 2 to 6 carbon atoms, aryl having from 6 to 10 carbon atoms, and N, 0, S, including heteroalkyl, e.g., heteroalkyl alkyl having one or more of said hetero atoms and from 1 to 10 carbon atoms or from 1 to 6 carbon atoms.
The present invention includes use of both racemic mixtures and optically active stereoisomers of compounds of formula III. Typically preferred are optically active compounds where the chiral carbon of the lactone moiety (i.e., the ring carbon of position 4 as depicted in formula III above) is of the (R) configuration according to the Cahn-Ingold-Prelog nomenclature system. See Carey, F.A. , Advanced Organic Chemistry. Part A, p. 65-66 (2d ed., Plenum Press 1984).
Such compositions of compounds of formula I or IA used in combination with one or more compounds of formula II and/or III may be employed alone or in combination with acceptable carriers such as those described below. For the treatment of immunodeficiency viral infections, for example an HIV infection, suitable effective dose of a compound of formula II in such a composition will be in the range of 1 to 5,000 μg per kilogram body weight of recipient per day, preferably in the range of 10 to 4,000 μg per kilogram body weight of recipient per day; and a suitable effective dose of a compound of formula III in such a composition will be in the range of 0.4 to 10,000 μg per kilogram body weight of recipient per day, preferably in the range of 5 to 500 μg per kilogram body weight of recipient per day. When the compounds are administered together it is expected one can use the lower portion of these ranges with excellent results.
One or more compounds of formula I or formula IA may be administered alone, or as part of a pharmaceutical composition, comprising at least one compound of formula I or IA together with one or more acceptable carriers thereof and optionally other therapeutic ingredients, including those therapeutic agents discussed. supra such as one or more compounds of formula II or III. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The compositions include those suitable for oral, rectal, nasal, topical (including buccal and sublingual) , vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form, e.g., tablets and sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy.
Such methods include the step of bringing into association the to be administered ingredients with the carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, liposomes or finely divided solid carriers or both, and then if necessary shaping the product.
Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion, or packed in liposomes and as a bolus, etc.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
Compositions suitable for topical administration include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and outhwashes comprising the ingredient to be administered in a suitable liquid carrier.
Compositions suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising one or more compounds of the present invention and a pharmaceutically acceptable carrier. A suitable topical delivery system is a transdermal patch containing the ingredient to be administered.
Compositions suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
Compositions suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size, for example, in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. , by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be
stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.
All documents mentioned herein are incorporated herein by reference.
The present invention is further illustrated by the following examples. These examples are provided to aid in the understanding of the invention and are not to be construed as limitations thereof.
GENERAL COMMENTS
The following reagents and procedures were employed as specified in the examples.
Virus. HIV-1 was obtained from the culture supernatant of HTLV-IIIB-producing H9 (H9/HTLV-IIIB) cells. During the exponential phase of growth, cell free supernatant was harvested, standardized for reverse transcriptase (RT) activity, and frozen in aliquots at -70°C. Clinical isolates of HIV-1 were prepared from patients testing positive for the human immunodeficiency virus, and standardized for RT activity.
Cells. Cell clone 293.27.2 (23), obtained from L.A. Herzenberg (Stanford University) , was derived from human
embronic kidney epithelial cells, which were cultured in Dulbecco's modified Eagle's medium (GIBCO) supplemented with 10% Fetal Calf Serum (FCS, obtained from Sigma) plus L-glutamine. See, e.g. Roederer, M. , et al., Proc. Natl. Acad. Sci. USA. 87:4884-4888 (1990). This cell clone had been stably transfected with PNAZ, which is an expression construct of lacZ gene driven by HIV-1 LTR. Expression of ?-galactosidase can be greatly induced by PMA or TNFα. Human peripheral blood mononuclear cells (PBMC) were prepared by Ficoll-Hypaque gradient centrifugation of blood from HIV-seronegative individuals, and cultured in RPMI 1640 supplemented with 20% FCS (Sigma) , penicillin, streptomycin, and L-glutamine in the presence of PHA (3 μg/ml). RPMI 8402 cell line, a present from Toshiwo Ando (Aichi Cancer Research Institute, Nagoya, Japan) , is a human T lymphatic cell line. It was grown in RPMI 1640 medium supplemented with 15% FCS and L-glutamine.
Stock Solution. A stock solution of curcumin was prepared in ethanol at a 10 mM concentration. Aliquots of the stock solution were stored frozen at -20°C.
Quantitation of HIV-1 LTR directed gene expression. Exponentially growing 293.27.2 (L.A. Herzenberg of Stanford University) cells were plated in 6 well plates at 2 x 10s cells per well in 2 ml of growth medium. After 48 hours, cells were stimulated with 40 u/ml of TNFα (Genzy e, Cambridge, MA) or 2 ng/ml of PMA (Sigma) . Various concentrations of the specified compound were added to the medium at designated times after stimulation with final concentrations of ethanol at less than 0.1% (vol/vol) . After 6-8 hours incubation at 37°C, medium was aspirated, cells were harvested, washed harvested, washed 4 times with PBS, and lysed in lacZ buffer (60 mM Na2HP04, 40 mM NaH2P04, 10 mM' KC1, 1 mM MgS04) . β-Galactosidase activities of cell lysates were quantitated by using ONPG as substrate. See, e.g. Herbomel, et al., Cell.
3_9:653-662 (1984). Protein concentration was measured. Cell viability was determined by the colony formation assay after cells were treated as above.
Treatment in acute HIV-1 infection. PBMC, after 72 hours stimulation with 3 μg/ml PHA, were infected with either HTLV-IIIg or a clinical isolate of HIV-1 at 1 reverse transcriptase unit (RTU) per 10 cells. Infection was carried out at 37°C for 2 hours. Then PBMC were washed with PBS to remove free virus and replated at 4.5 X 106 cells per well in 2 ml medium in the absence or presence of different concentrations of drugs. The cells were then continuously exposed to drugs for 6 days. On day 3, 1 ml of medium was removed from each well and replaced with 1 ml of fresh media containing drug at the previous concentration. On day 6, cells and media were harvested. Cell viability was determined by the trypan blue exclusion method and MTT metabolic assays. See, e.g. Mosman, T. , J. Immunological Methods. 61:55-63 (1983). P24 levels in the culture supernatant were quantitated by ELISA assay with HIV-1 P24 Antigen Kinetics Assay Kit (Coulter, Hialeah, FL) . RNA of HIV-1 reverse transcriptase was assayed with HIV-1 RNA Detection Kit (GeneTrak, Framingham, MA) according to manufacturer's instructions. Briefly, total cellular RNA was prepared, dot blotted onto a nitrocellulose membrane, and hybridized with 32P labeled probe for RT RNA.
EXAMPLE 1
293.27.2 cells were plated in 6 well plates at 2 X 10s cells/well in 2 ml of growth medium (DMEM) . TNFα (40 u/ml) and PMA (2 ng/ml) together with various concentrations of curcumin as indicated in Figure 1 were added to culture media 48 hours after the cells were plated. Six hours after addition of the curcumin, cells were harvested and 3-galactosidase activity was measured with ONPG as the substrate with results
depicted in Figure 1. Enzymatic activity is expressed as percentage of maximum expression which is referred to that in drug untreated sample (taken as 100) .
EXAMPLE 2
Human PBMC were infected with HIV-1 (HTLV-IIIg) at 37°C for 2 hours. Free virus were removed by wash with PBS. Infected PBMC were then aliquot into cells at 4.5 X 10s cells/well. Various concentrations of curcumin as indicated in Figure 2 were added to culture media. After 6 days, cell viability was determined by trypan blue exclusion, P24 levels were determined as described in the General Comments above. The results shown in Figure 2 are representative of two independent studies for which each data point was obtained from duplicate samples.
EXAMPLE 3
In a chronically infected T-lymphocyte and the promyelocytic cell line OM10.1, inhibition of P24 antigen was seen at IC^g - 4.58 μM following treatment with curcumin whereas AZT and ddl had little effect. The cell line OM10.1 contains one copy of HIV-1 per cell integrated into its genome and continually produces a low of HIV-1 proteins. This cell line was kindly supplied by NIH-AIDS Research and Reference Reagent Program.
This invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of the disclosure, may make modification and improvements with the spirit and scope of the invention.
Claims
1. A pharmaceutical composition comprising a pharmaceutical acceptable carrier and an effective antiviral treatment amount of a compound of the formula I:
R4 R5
X is selected from the group consisting of hydrogen and a chemical bond, R is selected from the group consisting of hydroxy and substituted alkylene, and R through Re are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom, and substituted and unsubstituted heteroalkyl, adapted for treating a mammal having an immunodeficiency virus.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective treatment amount of compound of the formula IA:
wherein the value n is an integer from 1 to 20, X and X' are each independently selected from the group consisting of hydrogen and a chemical bond, R^ through IQ are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstuted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom, and substituted and unsubstituted heteroalkyl, adapted for treating a mammal having an immunodeficiency virus.
3. A method of inhibiting or reducing the expression of genes operably linked to a LTRof an immunodeficiency virus which comprises administering an effective gene expression reduction amount of a compound of the formula I:
R R5
X is selected from the group consisting of hydrogen and a chemical bond, R is selected from the group consisting of hydroxy and substituted alkylene, and R^ through R5 are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom, and substituted and unsubstituted heteroalkyl.
4. A method of inhibiting or reducing the expression of genes operably linked to an LTR of an immunodeficiency virus which comprises administering an effective gene expression reduction amount of a compound of the formula IA:
wherein the value n is an integer from 1 to 20, X and X' are each independently selected from the group consisting of hydrogen and a chemical bond, R-i through RIQ are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom, and substituted and unsubstituted heteroalkyl.
5. A method for treating cells infected with a virus capable of causing an immunodeficiency disease in a human, comprising administering to the cells an effective antiviral treatment amount of a compound of the following formula I:
X is selected from the group consisting of hydrogen and a chemical bond, R is selected from the group consisting of hydroxy and substituted alkylene, and R-. through Re are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom, and substituted and unsubstituted heteroalkyl.
6. A method for treating cells infected with a virus capable of causing an immunodeficiency disease in a human, comprising administering to the cells an effective antiviral treatment amount of a compound of the following formula IA:
wherein the value n is an integer from 1 to 20, X and X' are each independently selected from the group consisting of a chemical bond and hydrogen, and R-, through RIQ are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom, and substituted and unsubstituted heteroalkyl.
7. A method of treating a human having an immunodeficiency disease comprising administering to said human an effective immunodeficiency disease treatment amount of a compound of the following formula I:
X is selected from the group consisting of a chemical bond and hydrogen, R is selected from the group consisting of hydroxy and substituted alkylene, and R*j_ through R5 are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom, and substituted and unsubstituted heteroalkyl.
8. A method of treating a human having an immunodeficiency disease comprising administering to said human an effective immunodeficiency disease treatment amount of a compound of the following formula IA:
wherein the value n is an integer from 1 to 20, X and X' are each independently selected from the group consisting of a chemical bond and hydrogen, and R through R^Q are each independently selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, a heteroatom, and substituted and unsubstituted heteroalkyl.
9. The immunodeficiency virus of claims 1, 2, 3, 4, 5, 6, 7 or 8, which is resistant to a reverse transcriptase inhibitor.
10. The reverse transcriptase inhibitor described in claim 9, which is selected from the group consisting of zidovudine (AZT), 2' ,3' -dideoxyinosine (ddl) and 2' ,3' -dideoxycytidine (ddC) .
11. The reverse transcriptase inhibitor described in claim 10 which is AZT.
12. The method of claims 3 or 4 wherein the LTR is an HIV LTR.
13. The compound described in claims 2, 4, 6 or 8 where n is a value of from 1 to 4.
14. The compound described in claim 1, 2, 3, 4, 5, 6, 7 or 8 where the compound of formula I or IA is curcumin.
15. The method of claim 5 or 6 where the cells are mammalian cells.
16. The method of claims 5 or 6 where the cells are human cells.
17. The method of claims 5 or 6 where the virus is capable of causing in the human acquired immune deficiency syndrome or an acquired immune deficiency syndrome related complex.
18. The method of claims 5 or 6 where the virus is HIV.
19. The method of claim 5 or 6 where the virus is HIV-1.
20. The method of claims 7 or 8 where the immunodeficiency disease is acquired immune deficiency syndrome or an acquired immune deficiency syndrome related complex.
21. The method of claims 7 or 8 in which the human has antibodies to the HIV virus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93347092A | 1992-08-21 | 1992-08-21 | |
US07/933,470 | 1992-08-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994004139A1 WO1994004139A1 (en) | 1994-03-03 |
WO1994004139A9 true WO1994004139A9 (en) | 1994-04-28 |
Family
ID=25464027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/007879 WO1994004139A1 (en) | 1992-08-21 | 1993-08-23 | Treatment of human viral infections |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1994004139A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
WO1997032587A1 (en) * | 1996-03-04 | 1997-09-12 | Dana-Farber Cancer Institute | Methods for treating viral infections |
US20030149113A1 (en) | 2001-10-12 | 2003-08-07 | Caplan Michael J. | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
WO2010029562A1 (en) * | 2008-09-09 | 2010-03-18 | Mukesh Harilal Shukla | Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same |
-
1993
- 1993-08-23 WO PCT/US1993/007879 patent/WO1994004139A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sarin et al. | Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone | |
WO1994004145A9 (en) | Treatment of human viral infections | |
WO1994004145A1 (en) | Treatment of human viral infections | |
CA1325594C (en) | Agents for the prophylaxis and therapy of retroviral infections | |
US5736527A (en) | Method of treating HIV in humans by administration of ddI and hydroxycarbamide | |
US5334612A (en) | Pharmaceutical compositions containing as active substance sulphur-containing carboxylic acids and their use in combating retroviruses | |
US5622959A (en) | Method of treating retroviral infections in mammals | |
Montefiori et al. | Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. | |
SK279804B6 (en) | Pharmaceutical composition for the treatment of adult t-cell leukemia/lymphoma | |
US9259433B2 (en) | Synergistic antiviral compositions comprising a viral attachment inhibitor, an integration inhibitor, and a proviral transcription inhibitor, and their use | |
TURANO et al. | Inhibitory effect of papaverine on HIV replication in vitro | |
NZ279619A (en) | Combating retroviral infection, use of bis(amidinobenzimidazole) compounds in medical treatment | |
WO1994004139A9 (en) | Treatment of human viral infections | |
WO1996011005A2 (en) | Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases | |
WO1994004139A1 (en) | Treatment of human viral infections | |
EP0655919A1 (en) | Treatment of human viral infections | |
US5519028A (en) | Antiviral preparations | |
WO1997037661A1 (en) | Preventive and remedy for viral infections | |
Geleziunas et al. | Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages | |
EP1311266A2 (en) | Combination hiv therapy including camptothecin | |
AU639273B2 (en) | Use of a benzodiazepine and a phenylpyrrylketone derivative | |
US6787527B1 (en) | Methods of preventing and treating HIV infection | |
WO1992016200A1 (en) | The use of hydroxamic acid derivatives to inhibit viral replication | |
US7097862B2 (en) | Methods of inhibiting tumor necrosis factor | |
AU718325B2 (en) | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread |